Author Correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions

Correction to: Scientific Reports 10.1038/s41598-020-58362-3, published online 30 January 2020

In Figure 5A, the chemical structure is incorrect. As a result, the Figure legend,

“AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H₂O₂ in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.”

should read:

“AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures³⁷ (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H₂O₂ in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.”

The correct Figure 5 and its accompanying legend appear below as Figure 1.

Figure 1.

AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. (A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures³⁷ (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.